Amelioration of carcinogen-induced toxicity in mice by administration of a potentized homeopathic drug, Natrum Sulphuricum 200

Evidence-based Complementary and Alternative Medicine

Volumn 6, Issue 1, 2009, Pages 65-75

  Bhattacharjee, Nandini ^a   Pathak, Surajit ^a   Khuda Bukhsh, Anisur Rahman ^a  

^a UNIVERSITY OF KALYANI   (India)

Author keywords

Anti carcinogenesis; Azo dye induced liver cancer; Geno and cyto toxicity biomarkers homeopathic remedy; Mice

Indexed keywords

4 DIMETHYLAMINOAZOBENZENE; ACID PHOSPHATASE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GLUTATHIONE; HOMEOPATHIC AGENT; PHENOBARBITAL; SODIUM SULFURICUM; UNCLASSIFIED DRUG;

ACID PHOSPHATASE BLOOD LEVEL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHROMOSOME ABERRATION; CONTROLLED STUDY; GENOTOXICITY; HOMEOPATHY; LIPID PEROXIDATION; LIVER CANCER; LIVER CARCINOGENESIS; LIVER PROTECTION; LIVER TOXICITY; MICRONUCLEUS TEST; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPERMATOZOON ABNORMALITY;

EID: 60749133798     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nem067     Document Type: Article

References (51)

1. Ernst E. The current position of complementary/alternative medicine in cancer. Eur J Cancer 2003;39:2273-77.
2. Earnst E. Complementary or alternative therapies for osteoarthritis. Nat Clin Pract Rheumatol 2006;2:74-80.
3. Ricotti V, Delanty N. Use of complementary and alternative medicine in epilepsy. Curr Neurol Neurosci Rep 2006;6:347-53.
4. Simpson CA. Complementary medicine in chronic pain treatment. Phys Med Rehabil Clin N Am 2006;17:451-72.
5. Richardson MA, Straus SE. Complementary and alternative medicine: Opportunities and Challenges for cancer management and research. Seminars in Oncology 2002;29:531-45.
6. Chrystal K, Allan S, Forgeson G, Issacs R. The use of complementary and alternative medicine by cancer patients in New Zealand and regional cancer treatment center. New Zealand Med J 2003;116:1-8.
7. Molassiotis A, Panteli V, Patiraki E, Ozden G, Platin N, Madsen E, et al. Complementary and alternative medicine use in lung cancer patients in eight European countries. Complement Ther Clin Pract 2006;12:34-9.
8. Molassiotis A, Margulies A, Fernandez-Ortega P, Pud D, Panteli V, Bruyns I, et al. Complementary and alternative medicine use in patients with hematological malignancies in Europe. Complement Ther Clin Pract 2005;11:105-10.
9. Bensoussan M, Jovenin N, Garcia B, Vandromme L, Jolly D, Bouche O, et al. Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. Gastroenterol Clin Biol 2006;30:14-23.
10. Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus B. Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease. BMC Complement Altern Med 2006;6:19. doi: 10.1186/1472-6882-6-19. http://www.biomedcentral.com/1472-6882/6/19.
11. Biswas SJ, Khuda-Bukhsh AR. Effect of a homeopathic drug, Chelidonium, in amelioration of p-Dab induced hepatocarcinogenesis in mice. BMC Complement Altern Med 2002;2:1-16.
12. Biswas SJ, Khuda-Bukhsh AR. Evaluation of protective potentials of a potentized homeopathic drug, Chelidonium majus, during azo dye induced hepatocarcinogenesis in mice. Indian J Exp Biol 2004;42:698-714.
13. Biswas SJ, Pathak S, Bhattacharjee N, Das JK, Khuda-Bukhsh AR. Efficacy of a potentized homeopathic drug, Carcinosin-200, fed alone and in combination with another drug, Chelidonium-200, in amelioration of p-Dab induced hepatocarcinogenesis in mice. J Altern Complement Med 2005;11:839-54.
14. Pathak S, Das JK, Biswas SJ, Khuda-Bukhsh AR. Protective potentials of a potentized homeopathic drug, Lycopodium-30, in ameliorating azo dye induced hepatocarcinogenesis in mice. Mol Cell Biochem 2006;258:121-31.
15. Daust R, Molnar F. Cellular populations and mitotic activity in rat liver parenchyma during azo dye carcinogenesis. Cancer Res 1964;24:1898-1909.
16. IARC (International Agency for Research on Cancer). On the evaluation of carcinogenic risk of chemicals to man. Group-2B 1987;7:449.
17. Ohnishi S, Murata M, Degawa M, Kawanishi S. Oxidative DNA damage induced by an N-hydroxy metabolite of carcinogenic 4-dimethylaminoazobenzene. Jpn J Cancer Res 2001;92:23-9.
18. Merkulova TI, Kropachev KY, Timofeeva OA, Vasiliev GV, Levashova ZB, Ilnitskaya SI, et al. Species-specific effects of the hepatocarcinogens 3′- methyl-4-dimehylaminoazobenzene and ortho-aminoazotoluene in mouse and rat liver. Mol Carcinog 2005;44:223-32.
19. Biswas SJ, Khuda-Bukhsh AR. Cytotoxic and genotoxic effects of the azo-dye p-dimethylaminoazobenzene in mice: A time-course study. Mutat Res 2005;587:1-8.
20. Siemiatycki J, Richardson L, Straif K, Latreille B, Lakhani R, Campbell S, et al. Listing occupational carcinogens: research Review. Environ Health Perspect 2004;112:1447-59.
21. NTP. Report on Carcinogens. (11th edn). Research Triangle Park, NC: National Toxicology Program. 2005 (Retrieved from http://ntp.niehs.nih. gov/index.cfm?Objectid=32BA9724-F1F6-975E-7FCE50709CB4C932.).
22. IARC (International Agency for Research on Cancer). Phenobarbital and Sodium salt. IARC monograph 2001;79:161.
23. White SJ, McLean AEM, Howland C. Anticonvulsant drugs and cancer, A cohort study in patients with severe epilepsy. Lancet 1979;ii:458-61.
24. Lee GH. Paradoxical effects of phenobarbital on mouse carcinogenesis. Toxicol Pathol 2000;28:215-25.
25. Kinoshita A, Wanibuchi H, Morimura K, Wei M, Shen J, Imaoka S, et al. Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression. Carcinogenesis 2003;24:1389-99.
26. Biswas SJ, Pathak S, Khuda-Bukhsh AR. Assessment of the genotoxic and cytotoxic potential of an antiepileptic drug Phenobarbital, in mice: A time course study. Mutat Res 2004;563:1-11.
27. Palekar SD, Sirsat SM. Studies on the hepatocyte in azo dye carcinogenesis. Indian J Exp Boil 1966;4:73-8.
28. Boericke W. Pocket Manual of Homeopathic Materia Medica Indian edn. Calcutta, India: Sett Dey and Co., 1976.
29. Kitagawa T, Sugano H. Enhancing effect of phenobarbital on the development of enzyme-altered islands and hepatocellular carcinomas initiated by 3′-methyl-4-(dimethylamino) azobenzene or diethylnitrosamine. Gann 1978;69:679-87.
30. Kitagawa T, Sugano H. Enhancement of azo-dye hepatocarcinogenesis with dietary phenobarbital in rats. Gann 1977;68:255-6.
31. Khuda-Bukhsh AR. Towards understanding molecular mechanisms of action of homeopathic drugs: An overview. Mol Cell Biochem 2003;253:339-45.
32. Khuda-Bukhsh AR. Laboratory research in homeopathy: pro. Integr Cancer Ther 2006;5:320-32.
33. Homeopathic Pharmacopoeia of India. Ministry of Health. Government of India Press, Coimbatore-641019: Controller of Publications, 1971;1:165.
34. Pathak S, Bhattacharjee N, Das JK, Chaki Chowdhury S, Roy Karmakar S, Banerjee P et al. Supportive evidences for anticancerous potential of an alternative medicine in hepatocarcinogenesis of mice. Res Com Med. June issue, 2007; 14:132 (DOI:10.1159/000102007).
35. Plaa GL, Amdun AM, Doull J, Klasser CD. Toxic responses of the liver, 4th edn. London UK: Pergamon Press, 1991.
36. Chan KY, Wong N, Lai PB, Squire JA, Macgregor PF, Behesthi B, et al. Transcriptional profiling on chromosome 19p indicated frequent down regulation of ACP5 expression in hepatocellular carcinoma. Int J cance 2005;114:902-8.
37. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver diseases. Dig Dis Sci 1988;33:1601-14.
38. Wiwanitkit V. High serum alkaline phosphatase levels, a study in 181 Thai adult hospitalized patients. BMC Family Practice 2001; 2:2 (retrieved from http://www.biomedcentral.com/1471-2296/2/2).
39. Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999;424:83-95.
40. Mishra S, Sharma DC, Sharma P. Studies of biochemical parameters in breast cancer with and without metastasis. Indian J Clin Biochem 2004;19:71-5.
41. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996;32A:30-8.
42. Jungst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, et al. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology 2004;39:1663-72.
43. Balasubramanian S, Kowdley KV. Effect of alcohol on viral hepatitis and other forms of liver dysfunction. Clin Liver Dis 2005;9:83-101.
44. Czeczot H, Scibior D, Skrzycki M, Podsiad M. Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochem Pol 2006;53:237-42.
45. Maclaughlin BW, Gutsmuths B, Pretner E, Jonas WB, Ives J, Kulawardane DV, et al. Effects of homeopathic preparations on human prostate cancer growth in cellular and animal models. Integr Cancer Ther 2006;5:362-72.
46. Jonas WB, Gaddipati JP, Rajeshkumar NV, Sharma A, et al. Can homeopathic treatment slow prostate cancer growth? Integr Cancer Ther 2006;5:343-9.
47. Adams LS, Seeram NP, Hardy ML, Carpenter C, Heber D. Analysis of the Interactions of Botanical Extract Combinations Against the Viability of Prostate Cancer Cell Lines. eCAM 2006;3:117-24.
48. Padmavathi B, Rath PC, Rao AR, Singh RP. Roots of Withania somnifera Inhibit Forestomach and Skin Carcinogenesis in Mice. Evid Based Compliment Alernat Med 2005;2:99-105.
49. Miller SC. Echinacea: a Miracle Herb against Aging and Cancer? Evidence In vivo in Mice. Evid Based Compliment Alternat Med 2005;2:309-14.
50. Pathak S, Multani AS, Banerjee P. Ruta 6 selectively induced cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer. Int J Oncol 2003;23:975-82.
51. Khuda-Bukhsh AR. Potentized homeopathic drugs act through regulation of gene expression: a hypothesis to explain their mechanism and pathways of action in vivo. Com Ther Med 1997;5:13-46.